QS Investors’s Cyclerion Therapeutics CYCN Stock Holding History

QS Investors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$453K	Hold	5,802	–	–	0.01%	777
2021 Q1	$324K	Buy	5,802 +672	+13%	+$50.5K	﹤0.01%	958
2020 Q4	$314K	Buy	+5,130	New	+$350K	﹤0.01%	973

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QS Investors's CYCN Position: Q2 2021 in Review

QS Investors held its Cyclerion Therapeutics (CYCN) position steady in Q2 2021 at 5,802 shares worth $453K. The position accounts for 0.01% of the portfolio, ranked #777.

QS Investors first reported a position in CYCN in Q4 2020 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold CYCN as of Q2 2021.

QS Investors held 5,802 shares of Cyclerion Therapeutics worth $453K as of Q2 2021.
QS Investors left its Cyclerion Therapeutics share count unchanged in Q2 2021.
Cyclerion Therapeutics made up 0.01% of QS Investors's portfolio in Q2 2021, its #777 holding.
QS Investors first reported a position in Cyclerion Therapeutics in Q4 2020 and has held it in 3 quarters since.
67 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.